XORTX Therapeutics Inc. (XRTX) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

High Risk
Significant dilution risk
Last updated: April 23, 2026

Risk Assessment Details

Potential Dilution: 2490.06% of current shares
Recent Dilution: 101.63% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
2.2M
Potential Supply
56M
Additional shares possible
Splits
None
Past 2 years

Summary

XRTX currently has 2.24M outstanding shares. with significant dilution risk as 55.8M authorized shares could dilute existing holders by 2490.1%. The company has significantly diluted shareholders by 101.63% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
Apr 23, 2026

POS AM filing: This POS AM filing includes information about the offering of common shares and pre-funded warrants by the company.

2.2M 56M
Mar 20, 2026

20-F filing | 7.0M shares outstanding

7M 61M
Sep 25, 2025

F-1 filing: This F-1 filing from XORTX Therapeutics Inc. includes information about a proposed offering of common shares, pre-funded warrants, and common warrants.

5.2M 61M
May 12, 2025

20-F filing | 3.8M shares outstanding

3.8M 56M
Nov 15, 2024

F-1 filing: This F-1 filing relates to the registration of common shares underlying warrants, with the selling shareholder receiving all proceeds from the sale of common shares and the company receiving proceeds from the exercise of warrants.

2.9M 56M
May 10, 2024

20-F filing | 2.0M shares outstanding

2M 55M
Aug 04, 2023

POS AM filing: This POS AM filing is for 3,341,900 common shares issuable upon exercise of common share purchase warrants.

15M 55M
Aug 04, 2023

POS AM filing: This POS AM filing describes the closing of an underwritten public offering on October 7, 2022, which included common share units and pre-funded warrant units, along with the granting of an option to purchase additional common shares and/or warrants.

15M 55M
Apr 28, 2023

20-F filing | 15.0M shares outstanding

15M 55M
Jan 27, 2023

F-3 filing: XORTX Therapeutics Inc. may offer and issue common shares, warrants and units up to an aggregate initial offering price of US$50,000,000.

13M 55M
Sep 30, 2022

POS AM filing: This is a POS AM filing for a potential offering of common stock. The filing includes information about expenses related to the offering and legal matters.

13M 0
Sep 08, 2022

F-1 filing: This is an F-1 filing detailing expenses related to a proposed offering, legal matters, experts, and SEC's position on indemnification.

13M 0
May 03, 2022

20-F filing | 13.0M shares outstanding

13M 0
Aug 12, 2021

F-1 filing: The F-1 filing contains information about the offer and sale of common shares, including costs and expenses related to the offering.

N/A 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime